An official State of Texas website.
Revision 24-2; Effective Sept. 20, 2024
3510 Financial Reconciliation Report (FRR)
Revision 24-2; Effective Sept. 20, 2024
The FRR is the annual reconciliation report submitted to HHSC. Each grantee must report final financial results as part of the closeout process on each contract. This report is due no later than 60 days after the end of the applicable contract term or 30 days after the last pay file is run, whichever is later. The grantee sends the completed form to fcs_finance@hhs.texas.gov.
3520 Match Report
Revision 24-2; Effective Sept. 20, 2024
Matching funds refer to non-federal resources such as money and in-kind contributions. The Centers for Disease Control and Prevention (CDC) requires the BCCS program to provide $1 in match for every $3 of CDC funding awarded. Grantees must secure, budget, expend and report the non-federal match. Match reports are submitted to HHSC 30 days after the end of each quarter to fcs_contracts@hhs.texas.gov.
3530 Clinical Performance Measures
Revision 24-2; Effective Sept. 20, 2024
Grantees are required to meet National Breast and Cervical Cancer Early Detection Program (NBCCEDP) performance measures. The following performance measures are used to assess, in part, the grantee’s effectiveness providing BCCS services. Screening indicators are as follows:
| PI No. | Service | Description |
|---|---|---|
| 1 | Cervical | Percentage of initial program pap tests provided to women 30 and older who have never or rarely been screened (Goal: >=35%) |
| 2 | Cervical | Percentage of pap test records with planned and completed diagnostic follow-up (Goal: >= 90%) |
| 3 | Cervical | Percentage of pap test records where time between screening and final diagnosis was <= 60 days (Goal: >= 75%) |
| 4 | Cervical | Percentage of pap test records with a diagnosis of HSIL, CIN2, CIN3/CIS or invasive cervical carcinoma where treatment has been started (Goal: >=90) |
| 5 | Cervical | Percentage of pap test records with a diagnosis of HSIL, CIN2 or CIN3/CIS where time between diagnosis and treatment is <= 60 days (Goal: >= 80%) |
| 6 | Breast | Percentage of mammogram screening records with abnormal results and completed diagnostic follow-up (Goal: >= 90%) |
| 7 | Breast | Percentage of mammogram screening records with completed follow-up and time between screening and final diagnosis was <= 60 days (Goal: >= 75%) |
| 8 | Breast | Percentage of breast cancer records with a diagnosis of CIS, other; DCIS; or invasive breast cancer that have treatment started (Goal: >= 90%) |
| 9 | Breast | Percentage of breast cancer records with a diagnosis of CIS, other; DCIS; or invasive breast cancer where time between diagnosis and treatment is <= 60 days (Goal: >= 80%) |
- A minimum of 35% of all NBCCEDP-reimbursed cervical cancer screenings should be provided to program-eligible women 30 and older who have never been screened or not screen within the last 10 years through the program. Grantees may use conventional or liquid-based cytology.
Cervical cancer diagnostic indicators are:
- A minimum of 90% of cervical screening records with planned and complete diagnostic follow-up.
- The interval between screening and final diagnosis of cervical cancer screenings should be 60 days or less for a minimum of 75% of the women.
- A minimum of 90% of cervical cancer records with final diagnosis of HSIL, CIN2, CIN 3, CIS or invasive cervical cancer must have started treatment.
- The interval between final diagnosis and initiation of treatment for HSIL, CIN2, CIN3, CIS or invasive cervical cancer should be 60 days or less for a minimum of 80% of the women.
Breast cancer diagnostic indicators are:
- A minimum of 90% of mammogram screening records with abnormal results must have a completed diagnostic follow-up.
- The interval between completed follow-up and time between abnormal screening and final diagnosis should be 60 days or less for a minimum of 75% of women.
- A minimum of 90% of breast cancer records with a final diagnosis of CIS, other, or DCIS, or invasive breast cancer must have started treatment.
- The interval between final diagnosis and initiation of treatment for breast cancer records with a final diagnosis of CIS, other, or DCIS, or invasive breast cancer should be 60 days or less for a minimum of 80% of women.
Administrative indicators are:
- Grantees must serve a minimum of 85% of proposed unduplicated clients.
- Grantees must expend a minimum of 95% of the awarded funds.
- Grantees must submit quarterly match reports 30 days after the end of each quarter.
Grantees must comply with and use Med-IT®, an online database system, to collect and process breast and cervical data, reports and billing per the business requirements of the program, including Med-IT® data entry, within 45 days of services provided.
Note: These performance measures are subject to change.